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Abstract
Here, we describe a novel member in the group of
membrane-anchored chymotrypsin (S1)-like serine pro-
teases, namely testis serine protease 1 (T-SP1), as it is
principally expressed in testis tissue. The human T-SP1
gene encompasses 28.7 kb on the short arm of chro-
mosome 8 and consists of seven exons. Rapid amplifi-
cation of cDNA ends (RACE) experiments revealed that
due to alternative splicing three different variants (T-SP1/1,
-2, -3) are detectable in testis tissue displaying pro-
nounced heterogeneity at their 39-end. T-SP1/1 consists
of an 18 amino acid signal peptide and of a 49 amino
acid propeptide. The following domain with the catalytic
triad of His108, Asp156, and Ser250 shares sequence iden-
tities of 42% and 40% with the blood coagulation factor
XI and plasma kallikrein, respectively. Only T-SP1/1 con-
tains a hydrophobic part at the C-terminus, which pro-
vides the basis for cell membrane anchoring. Using a
newly generated polyclonal anti-T-SP1 antibody, expres-
sion of the T-SP1 protein was found in the Leydig and
Sertoli cells of the testis and in the epithelial cells of the
ductuli efferentes. Notably, T-SP1 protein was also
detectable in prostate cancer and in some ovarian cancer
tissues, indicating tumor-related synthesis of T-SP1
beyond testis tissue.
Keywords: alternative splicing; catalytic triad; leydig
cells; ovarian cancer; prostate cancer; sertoli cells;
testis serine protease 1 (T-SP1).
Introduction
Serine proteases are found in a wide range of tissues and
biological fluids, playing crucial roles in the development
and maintenance of the organism, including fertilization,
immune responses, wound healing, blood coagulation,
and digestion. Furthermore, these proteases contribute
These authors contributed equally to this work.a
to many diseases and are particularly involved in multiple
organ failure due to sepsis and trauma (Jochum et al.,
1994; Waydhas et al., 1996), as well as tumor progres-
sion (Johnsen et al., 1998; Foekens et al., 2003; Reuning
et al., 2003; Yousef and Diamandis, 2003).
A new group of the chymotrypsin (S1)-like serine
proteases was recently identified that contain domains
which anchor them to the plasma membrane (Netzel-
Arnett et al., 2003). A subgroup of the membrane-bound
serine proteases which is anchored via a GPI-linkage
includes prostasin (Yu et al., 1995; Chen et al., 2001) and
testisin (Hooper et al., 1999, 2000), two proteases with
an expression pattern being restricted to the male genital
tract. While prostasin is mainly detectable in the prostate
gland, testisin is specifically expressed by testicular germ
cells during the premeiotic stage of spermatogenesis
(Hooper et al., 1999). Structural features and specific
expression patterns of testisin suggest that it regulates
proteolytic events associated with testicular germ cell
development (Hooper et al., 1999, 2000). Further serine
proteases which seem to play a (patho)physiological role,
especially in the male genital tract or in cancer progres-
sion, belong to the human kallikrein-related peptidases
(Lundwall et al., 2006; Paliouras and Diamandis, 2006;
Whitbread et al., 2006; Lundwall and Brattsand, 2008),
encoded by the kallikrein gene locus which comprises 15
serine protease genes (Yousef et al., 2000; Clements
et al., 2001) with prostate-specific antigen (KLK3) as one
of the best known representatives (Yousef and Diaman-
dis, 2003; Lilja et al., 2008).
Due to our interest in kallikreins (especially plasma kal-
likrein) (Neth et al., 2001, 2005; Fink et al., 2007), we
searched for transcripts encoding related enzymes in the
human genome. Our search in the NCBI database led to
a new family member of serine proteases which was first-
ly named ‘Similar to Plasma Prekallikrein Precursor’ or
GPI-SP1 (Netzel-Arnett et al., 2003).
mRNA expression profiling revealed that this gene is
predominantly transcribed in testis. We therefore termed
this new protein as T-SP1 (testis serine protease 1). In
addition to the database protein sequences of T-SP1/1
and T-SP1/2, a third splice variant was detected, which
we termed T-SP1/3. Only T-SP1/1 encodes a chymotryp-
sin-like serine protease, which also contains a hydropho-
bic C-terminal sequence, suggesting a membrane-bound
localization. Immunohistochemical studies with a newly
generated polyclonal antibody revealed T-SP1 expres-
sion in Leydig and Sertoli cells of the testis, in the epi-
thelial cells of the ductuli efferentes, and interestingly also
in prostate cancer, as well as ovarian cancer tissues.
Results
Identification, cloning, and bioinformatics on T-SP1
Tissue-specific expression of human T-SP1 mRNA
Following the bioinformatics studies on T-SP1, we
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Figure 1 Analysis of human T-SP1 expression in human
tissues.
Quantitative RT-PCR was carried out on 16 different human tis-
sues using 1 ng cDNA. For that, a primer pair was used which
allows detection of all three T-SP1 splice variants simultaneous-
ly. GAPDH transcripts were quantified in the same cDNAs which
served as normalization control.
designed primers for the predicted coding sequence of
human T-SP1 according to the GenBank sequence
(NM_198464, Homo sapiens tryptophan/serine protease).
Tissue distribution of T-SP1 expression was analyzed by
quantitative PCR using 16 different human tissue cDNAs.
T-SP1-mRNA was expressed in low amounts exclusively
in testis, displaying a T-SP1/GAPDH ratio of 18.9=10-4
(Figure 1). NCBI unigene analysis revealed a total of 17
EST entries for T-SP1, 11 for testis tissue, 5 for brain
tissue, and 1 for an uncharacterized tissue. Interestingly,
neither the primer pair designed for qPCR nor that for the
amplification of the entire coding region detected T-SP1
expression in human brain tissue.
Cloning, transcript analysis, and exon-intron struc-
ture of the human T-SP1 gene To identify the tran-
scriptional start site(s) of T-SP1, we used poly(A)qmRNA
of human testis for RLM-RACE (RNA ligase-mediated
rapid amplification of cDNA ends). 59-RLM-RACE
ensures that only full-length 59-ends of mRNA molecules
with an intact cap structure are selectively reverse tran-
scribed and amplified by nested PCR. By analysis of 18
clones, nine different transcriptional start sites were
detected in close proximity, forming two clusters with 11
and 15 bp in length (Figure 2A). The most frequently
detected transcription start sites were at positions -97
(6 clones) and at -54 (3 clones). The resulting 59-untrans-
lated regions vary from 45 to 105 bp in length. No further
upstream exon was detected.
In a next step the 39-end of the T-SP1 transcript was
examined. Thereby, 39-RACE analysis revealed a marked
heterogeneity at the 39-tail resulting in T-SP1 mRNA-
molecules of different length. In total, we detected three
different splice variants encoding mRNA molecules with
open reading frames of 1059 bp, 831 bp, and 912 bp
(Figure 2B,C). The predicted preproT-SP1 proteins com-
prise 352, 276, and 303 amino acids with a molecular
mass of 38.9 kDa, 30.7 kDa, and 33.6 kDa, respectively.
Comparison of the mRNA sequences of all three variants
with the NCBI database revealed that entry NM_198464
is identical to variant T-SP1/1, and T-SP1/2 is represent-
ed by the mRNA BC033497, while T-SP1/3 is a newly
detected form. For the quantification of the different
splice variants, three separate, isoform-specific primer
pairs were designed. The results showed that the main
expression concerns T-SP1/1, whereas T-SP1/2 and T-
SP1/3 are transcribed in much lower amounts (T-SP1/1:
99.87%, T-SP1/2: 0.13% and T-SP1/3: -4=10-4%). For
T-SP1/1, the cDNA sequence with the corresponding
amino acid sequence is shown in Figure 2B.
The genomic structure of the T-SP1 gene (Figure 2A)
was deduced by comparison of the three T-SP1 tran-
scripts with the genomic T-SP1 sequence on chromo-
some 8 (8p23.1, range 2858342–2887039) in combina-
tion with the 59- and 39-RACE results. The results
revealed that T-SP1/1 is derived from exons 1, 2, 3, 4,
and 6, whereas T-SP1/2 is encoded by exons 1, 2, 3, 4,
and 7, and T-SP1/3 variant comprises exons 1, 2, 3, 4,
5, and 7 (Figure 2C), indicating that the human T-SP1
gene includes seven exons spanning approximately
28.7 kbp on chromosome 8p23.1 (Figure 2A). The
lengths of the exons (1–7) range from 81 to 349 bp and
those of the introns are between 1360 and 15 149 bp
(Figure 2A). Alternative splicing in the region of intron 4 up
to exon 7 causes excision of this sequence in T-SP1/2,
whereas the sequence of intron 5 up to exon 7 is
removed in T-SP1/3 (Figure 2C).
Protein structure of human T-SP1 and sequence iden-
tity with other human serine proteases The pre-
dicted preproproteins of all three T-SP1 variants start with
a typical 18-amino acid signal peptide for a nascent
secretory protein. According to bioinformatic analysis,
the propeptide of the zymogen begins with Gly19, the
propeptide comprises 49 residues and ends with Arg67
(Figure 2B).
In contrast to the common N-terminal part of the cat-
alytic domain, the C-terminal part is heterogeneous
among the three different T-SP1 splice variants. T-SP1/1
comprises a full-length serine protease domain of 228
amino acids, where all essential amino acids around the
catalytic triad (His108, Asp156, and Ser250) are highly con-
served (Figure 2B). Based on alignment and structural
data of other serine proteases (McMullen et al., 1991a,b)
in humans, T-SP1/1 disulfide bonds may be formed
between Cys53/Cys176, Cys93/Cys109, Cys189/Cys256, Cys222/
Cys235 and Cys246/Cys276 (Figure 3 A). The first of these
cysteine pairs is predicted to link the pro- and catalytic
domain, whereas the remainder are likely to form disul-
fide bonds within the catalytic domain. Interestingly, a
presumably unpaired Cys exists at residue 340 close to
the C-terminus. Hydropathy plot analysis of T-SP1/1
revealed that this free Cys is located within a highly hydro-
phobic sequence of 17 residues (WLLLCPLSHVLFRAILY),
which may function as an anchor to the plasma
membrane (Figures 2B and 3A). T-SP1 splice variants 2
and 3 are identical to isoform 1 up to the lysine residue
at position 247 (Figure 2B). In the following sequence
part, the highly conserved GDSGGP motif of chymotryp-
sin-like serine proteases which is also found in T-SP1/1
is absent in T-SP1/2 and T-SP1/3, respectively (data not
shown). Thus, with respect to the serine residue of the
catalytic triad of T-SP1/1 no conserved equivalent amino
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Figure 2 Genomic organization, nucleotide and amino acid sequence, and exon distribution of the human T-SP1 gene.
(A) Genomic organization of the human T-SP1 gene. The human T-SP1 gene consists of seven exons and six introns and encompasses
28.7 kb on human chromosome 8. Black boxes represent the seven exons (E1–E7) and the six introns are indicated by the black
line (I1–I6). Exon and intron lengths are indicated in parentheses. 59-RLM-RACE revealed transcription start sites at positions -105,
-97, -94, -60, -54, -53, -51, -46, and -45. Only the transcription start site at position -97 is indicated (TS), as this start site was the
preferred position for the initiation of transcription. The 39-untranslated regions are designated by a hatched box. His, Asp, and Ser
refer to the catalytic triad amino acids in exons 2, 3, and 6. (B) Nucleotide and amino acid sequences of human T-SP1/1. Nucleotides
are numbered on the left and amino acids on the right site. Residues of the catalytic triad are highlighted in bold circles. The putative
activation site (ITGG) is indicated by an arrow and cysteines are marked with boxes. The N-terminal signal sequence (18 aa) is
followed by the putative propeptide with 49 amino acids. The C-terminal hydrophobic region (17 aa) is underlined. The polyadenylation
signal is underlined in bold. The 59-untranslated region (105 bp) is indicated in cursive. The 39-untranslated region from T-SP1/1 (31 bp)
is also shown in cursive letters. The poly(A) tail starts at position 1196. T-SP1 encodes for an mRNA molecule which comprise an
open reading frame of 1059 bp giving rise to a protein with 352 amino acids. (C) Exon distribution of SP1 splice variants. T-SP1/1 is
encoded by exons 1–4 and 6, whereas T-SP1/2 is composed of exons 1–4 and 7. T-SP1/3 consists of exons 1–5 and 7. In
T-SP1/1 the active site Ser250 is encoded by exon 6. Due to the absence of exon 6 in T-SP1/2 and T-SP1/3, this highly conserved
region at Ser250 is absent in these splice variants.
acid sequence in the two other variants exists. Further-
more, the hydrophobic C-terminus is absent in the T-
SP1/2 and T-SP1/3.
To identify the nearest related protease members of
T-SP1/1, alignment studies were performed. The pre-
dicted amino acid sequence of the catalytic domain of
T-SP1/1 shares 42% and 40% identity with human coag-
ulation factor XI and plasma kallikrein (Figure 3B). A
slightly lower sequence identity was identified with the
male genital tract proteases testisin (36%), prostasin
(35%), acrosin (35%), and leydin (33%). With respect to
kallikrein-related peptidases, T-SP1/1 protein shares rea-
sonable sequence identity with the human KLK2 (32%)
and KLK13 (37%). In addition, T-SP1/1 shows 34%
sequence identity with trypsin (Figure 3B).
Recombinant expression, antibody generation, and
immunolocalization of T-SP1
Recombinant expression of proT-SP1 variants in
Escherichia coli For the production of specific anti-
bodies, we generated the antigens by recombinant
expression of proT-SP1/1, proT-SP1/2, and proT-SP1/3
in E. coli. After purification by Ni-affinity chromatography
the recombinant proteins were analyzed by SDS-PAGE
(data not shown). The protein yields after purification
ranged between 20 mg (proT-SP1/1), 25 mg (proT-SP1/
2), and 50 mg (proT-SP1/3) per liter E. coli culture.
Antibody generation Taking the relatively higher
expression rate of T-SP1/3 in E. coli into account, an anti-
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Figure 3 Predicted structure of human T-SP1 (A) and alignment of T-SP1/1 with related human serine proteases (B).
(A) The cDNA sequence predicts that T-SP1/1 is translated initially as a single chain, 352 amino acid precursor with a signal peptide
(black), propeptide (dark gray), a catalytic domain (light gray), and a hydrophobic stretch (patterned) at the C-terminus. We predict
that the signal peptide is removed co-translationally in the endoplasmic reticulum, leaving a proenzyme which is activated subse-
quently by hydrolysis of the propeptide segment at Arg67. This results in a 285-residue catalytic domain (heavy chain) through a
disulfide linkage involving Cys53 and Cys176. The location of other Cys-Cys pairs is shown by analogy to the Cys-pairings in human
plasma kallikrein. Also shown are positions of the catalytic triad residues found in all active serine proteases (His108, Asp156, and
Ser250, corresponding to His57, Asp102, and Ser195 using standard chymotrypsinogen numbering). (B) T-SP1/1 shows sequence identity
to human factor XI (42%), to human plasma kallikrein (PPK) (40%), and to human prostasin (38%). Sequence identity was found for
the serine proteases testisin (36%) and acrosin (35%). For leydin, the sequence identity was calculated at 33%. T-SP1/1 contains
the catalytic triad with His108, Asp156, and Ser250 (in bold letters and gray boxes). T-SP1/1 protein also shares sequence similarity with
kallikrein-related peptidase 2 (KLK2) (32%), and KLK 13 (37%).
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Figure 4 Immunohistochemical analysis of T-SP1 expression in testis tissue.
Immunohistochemical staining of testis tissue was performed using the purified anti-T-SP1 antibody as primary antibody. Intense
staining was detected in the Leydig and Sertoli cells of the testis (A, E, and F) and in the epithelial cells of the ductuli efferentes (B
and C). Weak staining was observed in the epididymis (C). Omitting the anti-T-SP1 antibody revealed no specific staining (D). Original
magnification 1000= (A, D, F) and 500= (B, C, E).
T-SP1 polyclonal antibody was generated by immunizing
rabbits with recombinant T-SP1/3. Owing to the substan-
tial amino acid sequence identity of 82% between variant
T-SP1/1 and T-SP1/3 one could expect effective cross-
reactivity of T-SP1/1 with anti-T-SP1/3 antibodies. The
generated polyclonal antibody detects the purified vari-
ants T-SP1/1, T-SP1/2, and T-SP1/3 in Western blot
experiments which were further confirmed by using the
anti-penta-His antibody for identification of the variants
via their C-terminal His-tag (data not shown).
Immunohistochemical detection of T-SP1 in testis
and cancer tissues Applying the polyclonal anti-T-
SP1 antibody for immunofluorescence detection, we
localized T-SP1 in the Leydig and Sertoli cells (Figure 4,
indicated by arrows) of the testis and the epithelial cells
of the ductuli efferentes (Figure 4A,B). Weak fluorescence
was also observed in the epididymis (Figure 4C). Omit-
ting the first antibody (negative control) revealed no
specific immunofluorescence (Figure 4D). Using a chro-
mogenic approach, staining was mostly overt in the
membranes of the Leydig cells, but bright areas were
also detected in the seminiferous tubules representing
Sertoli cells (Figure 4E,F, arrows), thus confirming the
fluorogenic data. To evaluate additional male genital tract
tissue, prostate tissue was chosen. Although no expres-
sion of T-SP1 protein was overt in normal prostate tissue
(Figure 5A), in glandular differentiated prostate carcinoma
(Gleason score 6) some cytoplasmic staining was detect-
able (Figure 5B,C,D, arrows). Finally, ovarian cancer tis-
sue sections of different morphological types were tested
for the expression of T-SP1 applying the chromogenic
staining method. Cytoplasmic staining of the T-SP1 pro-
tein was detected in groups of ovarian cancer cells with
weak membrane staining (Figure 5E–F, arrows).
Expression of T-SP1 isoforms in HEK293 cells To
study the subcellular localization of the T-SP1 splice vari-
ants, we designed fusion constructs with the fluorescent
protein EGFP at the C-terminus of each proT-SP1 splice
variant for transfection of HEK293 cells. Western blot
analysis carried out with an anti-EGFP antibody revealed
proT-SP1/1-EGFP mainly in the membrane part (Figure 6,
M1) of the cells and only in small amounts in the soluble
fraction (Figure 6, S1). The fusion protein was detected
at the predicted molecular mass of 64 kDa. In contrast,
proT-SP1/2 (55.7 kDa) and proT-SP1/3 (58.6 kDa) were
present primarily in the soluble fraction (Figure 6, S2 and
S3) in addition to minor quantities in the membrane frac-
tion (Figure 6, M2 and M3). These results suggest
membrane anchoring of proSP1/1, but not of proSP1/2
and proSP1/3.
Discussion
In this study, we describe cloning, recombinant expres-
sion, and initial characterization of a new membrane-
anchored human serine protease-like protein. According
to its main occurrence in testis tissue we now named this
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Figure 5 T-SP1 expression in prostate tissue, ovarian cancer
tissues, and prostate cancer tissue.
(A) No staining was detected in normal prostate tissue. (B, C, D)
Expression of T-SP1 in prostate cancer cells (arrows). (E–H) T-
SP1 expression was observed in cells of several ovarian cancer
tissues (arrows). Original magnification 100= (A, E) and 200= (B,
C, D, F, G, H).
Figure 6 Western blot analysis of recombinantly expressed
proT-SP1/1-EGFP forms in HEK293 cells.
ProT-SP1/1-EGFP was mainly detected in the membrane frac-
tion (M1) and only a minor amount was found in the soluble cell
fraction (S1), while proT-SP1/2-EGFP and proT-SP1/3-EGFP
were mainly detected in the soluble fraction (S2 and S3). For
detection of the fusion proteins, a mouse anti-EGFP antibody
and a secondary anti-mouse antibody (HRP-linked) were used
as described in the materials and methods section.
protein testis serine protease 1 (T-SP1). Using our PCR-
based assays we were not able to detect T-SP1 in human
brain tissue, although 5 EST entries in the UniGene data-
base also suggest expression of this protease-like pro-
tein in the brain. However, sequence alignment studies
revealed that none of the brain transcripts encode for the
full length coding sequence of T-SP1.
The T-SP1 gene is located on the short arm of chro-
mosome 8 and consists of 7 exons comprising approx-
imately 28.7 kbp. Apart from the database entry of the
mRNA sequences corresponding to variants T-SP1/1 and
T-SP1/2, we detected the transcript of a further splice
variant in testis tissues which we designated T-SP1/3. The
three mRNAs exhibit open reading frames of 1059 bp,
831 bp, and 912 bp, encoding preproproteins with pre-
dicted molecular weights of 38.9 kDa, 30.7 kDa, and
33.6 kDa, respectively. Immunohistochemical staining
with a newly developed polyclonal antibody occurred in
the Leydig and Sertoli cells of the testis and in the epi-
thelial cells of the efferent ducts, indicating a potential
physiological role of the protein in this male genital tract
tissue.
Apart from a reasonable high sequence identity with
the coagulation enzymes factor XI (42%) and plasma kal-
likrein (40%) which arose from a common ancestor by
gene duplication (Beaubien et al., 1991), T-SP1/1 also
shares some sequence identity with other serine prote-
ases of the male genital tract, such as testisin (36%),
acrosin (35%), leydin (33%), and prostasin (35%). Testi-
sin belongs to the GPI-linked membrane-anchored pro-
teases and is mainly expressed in the testis (Hooper
et al., 1999, 2000). Moreover, it is found in some tumor
cell lines of other origin (Hooper et al., 2000) and in ovar-
ian tumors (Shigemasa et al., 2000; Tang et al., 2005).
For that reason, testisin is supposed to promote malig-
nant transformation in these tumor cells and may, there-
fore, become a valuable diagnostic marker in certain
tumor entities. Moreover, acrosin and leydin are also pre-
dominantly expressed in the testis. While acrosin has
been studied extensively and is well-characterized as an
active protease of the acrosome contributing to the fer-
tilization process (Klemm et al., 1991), leydin is described
only once in the literature as a component of the Leydig
cells (Poorafshar and Hellman, 1999). Up to now, just
cloning and some structural data, but no functional char-
acterization of this testis protein, have been presented.
In contrast to the latter two proteases, which do not
belong to the membrane-bound serine proteases, the
GPI-anchored prostasin is primarily expressed in the
prostate gland and some cancer entities, but not in the
testis (Yu et al., 1995; Chen et al., 2001). Yet like testisin,
its structure and function is intensively studied (Chen et
al., 2004; Shipway et al., 2004) also revealing a prominent
role as a potential marker for ovarian cancer (Mok et al.,
2001). Interestingly, immunohistochemical staining of
T-SP1 with our newly generated polyclonal antibody illus-
trated a partial membrane localization of the protein in
testis tissue. In the cancer sections, T-SP1 revealed a
more cytoplasmic staining, indicating a putative intracel-
lular location. At this time, we cannot rule out the
possibility that in cancer tissues additional splice variants
of T-SP1 were transcribed, possibly without a signal
peptide.
Similarly, the human kallikrein-related peptidases,
KLK2 and KLK13 (Lundwall et al., 2006), which show a
sequence identity of 32% and 37%, respectively, with the
catalytic domain of T-SP1/1, are highly expressed not
only in testis but also in ovarian cancer tissues (Tremblay
et al., 1996; Petraki et al., 2003; Scorilas et al., 2004;
Dorn et al., 2007). Furthermore, KLK5 is upregulated in
malignant ovary tissue (Kim et al., 2001), and KLK9 and
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KLK10 have been described as prognosis markers in
ovarian cancer (Yousef and Diamandis, 2003). Therefore,
it seems possible that T-SP1 may also act as a marker
of certain tumors, because we could show its protein
expression in human ovarian cancer tissues as well as in
glandular differentiated prostate carcinoma, where it may
be upregulated by hormones. The latter assumption
seems to be underlined by the fact that the MatInspector
software (www.genomatix.de) calculates putative binding
sites for the progesterone receptor and the androgen
receptor 719 bp (TAagtcaTGTTCT) and 1642 bp (GGtt-
CActcTCTTCT) upstream of the transcription initiation
site of T-SP1. Thus, T-SP1 expression may be regulated
by progesterone and androgens which bind to these
receptors (Holdcraft and Braun, 2004; Gadkar-Sable et
al., 2005). A hormone-dependent regulation of kallikrein-
related peptidases has already been demonstrated in
breast and prostate cancer (Paliouras and Diamandis,
2006, 2008).
With respect to the molecular characterization of the
T-SP1 variants, we found a hydrophobic region of 17
amino acids at the C-terminus of T-SP1/1 (WLLL-
CPLSHVLFRAILY), suggesting that this variant is bound
to the plasma membrane. Interestingly, no hydrophobic
part at the C-terminus in the sequences of T-SP1/2 and
T-SP1/3 exists. A possible GPI-anchor for T-SP1/1 has
already been proposed by other investigators (Netzel-
Arnett et al., 2003). In this review article, T-SP1/1 was
classified to belong to a new member of GPI-anchored
serine proteases. This anchorage has already been
described for several membrane/GPI-bound serine pro-
teases, such as the male genital tract proteases prostasin
(Chen et al., 2001) and testisin (Hooper et al., 2000).
However, our own studies with phospholipase D treat-
ment of ectopically expressed T-SP1 in HEK293 cells did
not result in the release of T-SP1 into the cell culture
supernatant (data not shown).
To investigate the role of the different C-termini of the
three T-SP1 splice variants, we generated fusion con-
structs with the fluorescent protein EGFP at the C-
terminus of each T-SP1 isoform. Western blot analysis of
the ectopically expressed splice variants revealed that
the proT-SP1/1-EGFP protein is mainly located in the
membrane and only small amounts in the soluble fraction
of HEK293 cells. In contrast, the variants proT-SP1/2-
EGFP and proT-SP1/3-EGFP were primarily detected in
the soluble fraction and only in a very small amount in
the membrane fraction, suggesting that the C-terminal
part of proT-SP1/1 is responsible for membrane
anchorage.
For evaluation of the catalytic activity, the purified
recombinant T-SP1/1 from E. coli, HEK293 cells, and
Pichia pastoris were analyzed. In addition, incubation of
the proprotein with furin for zymogen activation was per-
formed, since the recognition sequence (an Arg at posi-
tions P1, P4 and P6) (Figure 2B) for cleavage by furin is
present in the proregion of proT-SP1/1. Up to now, none
of these approaches revealed any proteolytic activity
(data not shown).
In summary, we report for the first time the character-
ization of a new serine protease which is mainly ex-
pressed in human testis and, therefore, named by us as
testis serine protease 1 (T-SP1). Due to alternative splic-
ing three different variants of T-SP1 exist, but only T-SP1/
1 may play a physiological role in testis. We describe for
the first time the production of recombinant T-SP1 vari-
ants and the generation of polyclonal antibodies for
immunohistochemical detection. Thus, we demonstrated
the presence of T-SP1 in the Leydig and Sertoli cells of
the testis and in the efferent ducts, where it might be
involved in male fertility, as it has been recently described
for KLK14 (Emami et al., 2008). Additionally, under patho-
logical conditions T-SP1 is expressed in prostate cancer
and several ovarian cancer tissues and may therefore
serve as a novel marker of certain tumor entities.
Materials and methods
Bioinformatics for the analysis of the T-SP1 gene
and protein structure
The exon-intron structure of the human T-SP1 gene was ana-
lyzed by comparing the sequence of experimentally identified
T-SP1 transcripts with the genomic sequence available through
NCBI using the Blast software (www.ncbi.nlm.nih.gov/BLAST).
To identify putative polyA consensus sequences, the WebGene
software (www.itb.cnr.it/webgene) was employed. EST entries
for T-SP1 transcripts were analyzed using the EST Profile Viewer
software (www.ncbi.nlm.nih.gov). Splice variants of T-SP1 were
analyzed using the Aceview software (www.ncbi.nlm.nih.gov/
IEB/Research/Acembly). Amino acid and nucleic acid sequence
alignments were carried out with the SECentral software (Sci Ed
Central, Clone Manager Professional Suite 7.11, Cary, NC, USA).
Cloning of human T-SP1
The nucleotide sequence (NM_198464), encoding a putative ser-
ine protease, was extracted from the GenBank database during
an alignment study with human plasma prekallikrein. Based on
this nucleotide sequence, primers were designed for cloning of
the human T-SP1 cDNA (forward: 59-CCA TGC TCC TGT TCT
CAG TGT TG-39, reverse: 59-TCA GTA CAA AAT AGC TCT GAA
CAA CAC ATG GG-39). As a template, the human multiple tissue
cDNA panels I and II (Clontech, Mountain View, CA, USA) were
used. PCR was performed with 5 ml (1 ng) cDNA as template,
1 ml forward and reverse primer (200 nM), 1 ml dNTP mix
(200 mM each), 10= Hifi buffer (Invitrogen, Carlsbad, CA, USA),
MgSO4 (2 mM), 34.5 ml H2O, and 0.5 ml (2.5 U) Platinum Taq
Polymerase (Invitrogen) in a final volume of 50 ml. For thermo-
cycling, initial denaturation was carried out at 958C for 2 min
and amplification was achieved by 35 cycles at 958C for 15 s,
588C for 30 s, and 728C for 90 s, followed by a final single incu-
bation step at 728C for 10 min. Cloning of the PCR products
was performed using the pCR4-TOPO cloning kit (Invitrogen)
according to the protocol of the manufacturer, and the DNA
sequence of the clones was determined by a commercial service
(MediGenomix, Munich, Germany).
59-RLM-RACE and 39-RACE
Transcriptional start sites of T-SP1 were determined by perform-
ing RNA ligase-mediated rapid amplification of 59-cDNA ends
(Gene Racer Kit, Invitrogen) with 250 ng poly(A)q mRNA from
pooled human testis of 45 males in the age range of 14 to
64 years (Clontech). 59-RLM-RACE ensures that only full-length
59-ends of mRNA molecules with an intact cap structure are
selectively reverse transcribed and amplified by nested PCR. For
reverse transcription, random oligo-dT priming was employed.
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The T-SP1 specific primers for determination of the transcrip-
tional start sites used in primary and nested PCR were 59-CCA
GTC CAT GAT GAC CAT TG-39 and 59-AGG ATG GAG CCG CCA
CAG AA-39, whereas the primers 59-CGA CTG GAG CAC GAG
GAC ACT GA-39and 59-GGA CAC TGA CAT GGA CTG AAG GAG
TA-39 served as anchor oligonucleotides. To perform 39-RACE,
the oligonucleotides 59-GGA TTC TCA CTG CGG CTC AC-39 and
59-GTG CCG GAT ACA AGA ATG AG-39 were used as gene-
specific primers, while 59-GCT GTC AAC GAT ACG CTA CGT
AAC G-39 and 59-CGC TAC GTA ACG GCA TGA CAG TG-39
posed as adapter primers. First and nested PCR were carried
out at 958C for 2 min and amplification was achieved by 35
cycles at 958C for 15 s, 528C for 30 s, and 728C for 90 s, fol-
lowed by a final single incubation step at 728C for 10 min. The
PCR products were cloned into the plasmids pCR2.1-TOPO
(Invitrogen) and the DNA sequences of the inserts determined
as described above.
Detection of T-SP1 transcript expression in human
tissue
Quantitative RT-PCR was carried out using a LightCycler (Roche,
Mannheim, Germany) and a LightCycler-FastStart DNA Master
SYBR Green I Kit (Roche). Primer sets for the simultaneous as
well as separate quantification of all T-SP1 splice variants were
designed by Search LC (Heidelberg, Germany). PCR was per-
formed with 1 ml cDNA (1 ng) of the human multiple tissue cDNA
panels I and II (Clontech) as template, 2 ml primer set (Search
LC), 2 ml LC-FastStart DNA Master SYBR Green I mix, and 15ml
H2O. Thermocycling was carried out as follows: initial denatur-
ation was carried out at 958C for 10 min and amplification was
achieved by 45 cycles at 958C for 10 s, at 688C for 10 s, and at
728C for 16 s. Specificity of quantitative PCRs was verified by
melting curve analysis and agarose gel electrophoresis.
Expression of recombinant proT-SP1 variants in
E. coli and protein purification of proT-SP1
Clones of the three variants of proT-SP1 in the pCR2.1-TOPO
vector as described in 59-RLM-RACE and 39-RACE were used
as templates. Primers for proT-SP1 were 59-AAG CCG GCCCAC
GGA CTC CTC TCC CAG-39 as forward and 59-CCG CTC GAG
TTT TGC AGA TGA AAG GTG TG-39 as reverse primer for proT-
SP1/1 and 59-CGG CCT CGA GTA CAA AAT AGC TCT GAA CAA
C-39 as reverse primer for proT-SP1/2 and proT-SP1/3, respec-
tively. PCR was performed using the following conditions: dena-
turation occurred at 958C for 2 min and amplification was
achieved at 958C for 15 s, 568C for 30 s and 728C for 90 s for
35 cycles, and final extension was at 728C for 10 min. The PCR
product was digested with NaeI and XhoI and ligated into the
pENTR11 vector (Invitrogen). For recombinase reaction, 300 ng
pENTR11 vector with insert was incubated with 300 ng pET-
DEST42 vector and a LR-clonase-mix (Invitrogen) at 258C for 1 h
according to the manufacturer’s protocol. After a digestion with
proteinase K at 378C for 10 min, the mixture was used to trans-
form the E. coli strain TOP 10 (Invitrogen). Selection was carried
out with 200 mg/ml ampicillin and colonies with the correct insert
were sequenced by Sequiserve, Munich, Germany. Plasmids
with correct in-frame sequences were selected for further stud-
ies. The E. coli strain BL21(DE3) was transformed with the
respective plasmids for expression of recombinant proT-SP1/1,
-SP1/2 and -SP1/3. Expression was induced with 0.5 mM iso-
propyl-thio-b-D-galactoside (IPTG) at an OD600 of 0.4 at 378C
and E. coli cells were harvested 3 h after induction. Inclusion
bodies were isolated with BugBuster reagent (Novagen, Darm-
stadt, Germany) according to the instructions of the manu-
facturer. Briefly, inclusion bodies were dissolved in loading buffer
(8 M urea, 100 mM NaH2PO4, 10 mM Tris-HCl, pH 8) and applied
on a 1-ml HisTrap nickel column using the A¨KTAexplorer system
(GE Healthcare, Waukesha, WI, USA). After washing with 5=col-
umn volumes of washing buffer (8 M urea, 100 mM NaH2PO4,
10 mM Tris-HCl, pH 6.3) recombinant protein was eluted with
elution buffer (8 M urea, 100 mM NaH2PO4, 10 mM Tris-HCl, pH
5.9). Absorbance was monitored at the wavelength at 280 nm.
Aliquots of eluted fractions were subjected to SDS-PAGE and
stained with Coomassie Blue and assayed for His6-tag immu-
noreactivity. Recombinant protein was analyzed by amino acid
sequencing performed with a gas-phase sequencer (Procice 492
cLC, Applied Biosystems, Darmstadt, Germany) using standard
conditions.
Production of polyclonal anti-T-SP1-antibodies
The purified recombinant T-SP1/3 was used as an antigen to
immunize rabbits. Protein (60 mg) was injected intramuscularly
in two New Zealand white female rabbits. T-SP1/3 was diluted
1:1 in complete Freund’s adjuvant for the first injection and in
incomplete Freund’s adjuvant for the following injections. Boosts
were carried out 3 times every 3–4 weeks and blood was drawn
from the animals and tested for antibody generation in an indi-
rect ELISA.
Anti-T-SP1 antibodies were purified with DEAE Fast Flow
Sepharose (GE Healthcare) using the Bio Pilot system (GE
Healthcare). The DEAE column was equilibrated with 20 mM Tris,
pH 8.5 and rabbit serum was dialyzed in the same buffer and
applied to the column. Elution of the IgGs was carried out using
a sodium chloride gradient (20 mM Tris, pH 8.5, 1 M NaCl). IgG
fractions were analyzed via SDS-PAGE and Coomassie Blue
staining.
Immunohistochemistry
Immunohistochemical staining of paraffin embedded testis
tissue slides (Biocat, Heidelberg, Germany) was performed
according to the manufacturer’s instructions. Briefly, the primary
anti-T-SP1/3 antibody was used in a dilution of 1/60 and incu-
bated overnight at 48C. The secondary anti-rabbit-IgG antibody
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was
labeled with rhodamine and used in a dilution of 1/100. The
slides were embedded with Prolong Antifade (Molecular Probes,
Eugene, OR, USA) and analyzed using a fluorescent microscope
(IX50 Olympus, Hamburg, Germany). Immunohistochemical
staining of testis and diverse cancer tissues with a chromogenic
substrate was performed with the AP Polymer System (Zyto-
med, Berlin, Germany) according to the instruction of the man-
ufacturer with a dilution of the anti-T-SP1/3 antibody of
1/150.
Expression of recombinant T-SP1/1 in HEK293 cells
EGFP fusion constructs of proT-SP1 variants with the fluores-
cent protein EGFP at the C-terminus were obtained with a full-
length cDNA cloned into the pCR2.1-TOPO vector as a
template. The preproprotein of T-SP1 with its hydrophobic C-
terminus was created by PCR with the forward oligonucleotide
59-GGA ATT CAT GCT CCT GTT CTC AGT GTT GCT-39 with an
EcoRI restriction site at the 59-end and the reverse primer 59-
CGG GAT CCG TAC AAA ATA GCT CTG AAC AAC ACA TGG-
39 or 59-CGG GAT CCG TTT TGC AGA TGA AAG GTG TGA
GAC-39 with a BamHI restriction site at the 39-end. PCR condi-
tions were as follows: denaturation occurred at 958C for 2 min
and amplification was achieved at 958C for 15 s, 568C for 30 s
and 728C for 90 s for 35 cycles and final elongation was at 728C
for 10 min. The PCR product was digested with EcoRI and
BamHI and ligated into the equally restricted pEGFP-N3 vector
(Clontech).
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For transfection with the pEGFP-N3-T-SP1 constructs, HEK
293 cells were plated in a 6-well dish at a density of 30–50%
per well containing 2 ml Dulbecco’s modified Eagle’s medium
(PAA, Pasching, Austria) with 10% fetal bovine serum and 40
U/ml penicillin/streptomycin. The cells were transfected by ex-
posure to 2 mg plasmid DNA plus 3 ml lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol. After
1 day, cells were split into 10-cm dishes and cultured for 14 days
in the presence of 1 mg/ml G418 (PAA) to select stable trans-
fected cells. Surviving cells were pooled and further expanded
in 75-cm2 flasks under the selection of 100 mg/ml G418.
Preparation of soluble and membrane protein
fractions in proT-SP1-EGFP expressing HEK293
For the preparation of membrane and cytosolic fractions of
HEK293 cells, confluent cells from a 6-well plate were scraped
and centrifuged at 2000 g for 15 min at room temperature. The
cell pellet was resuspended in lysis buffer (50 mM NaH2PO4,
50 mM Na2HPO4, 200 mM NaCl, 5 mM EDTA, 1% Triton-X 100,
pH 6) with a protease inhibitor cocktail III (Calbiochem/Merck,
Darmstadt, Germany) and sonified 3 times for 2 s. Followed by
a centrifugation step at 2000 g for 15 min at 48C, the supernatant
(cytosolic fraction) was collected for further analysis. The
remaining pellet (membrane fraction) was resuspended in RIPA
buffer (50 mM Tris-Cl, pH 8, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate and 0.1% SDS) and rocked on ice for 1 h.
Finally, centrifugation was carried out with 10 000 g for 30 min
at 48C. The supernatant was further examined by Western blot
analysis.
Western blotting of recombinant T-SP1 variants
Purified proteins were separated under reducing conditions by
SDS/PAGE on a 12.5% gel or on a gradient gel (4–15%; Bio-
Rad, Hercules, CA, USA) and then transferred by electroblotting
onto a nitrocellulose membrane (Whatman, Dassel, Germany).
The membrane was blocked using blocking buffer w10 mM Tris-
Cl pH 7.5, 150 mM NaCl, 0.1% Tween-20 (v/v), 3% bovine serum
albumin (BSA)x for 1 h at room temperature and incubated with
a Penta-His-Conjugate (Qiagen, Hilden, Germany) against the
His6-tag linked with HRP (Qiagen) in a dilution of 1:3000 for 1 h
at room temperature. Visualization was achieved by the
enhanced chemiluminescence system ECL Plus (GE Healthcare)
according to the instructions of the supplier.
For additional detection of T-SP1 the generated polyclonal
antibody was used. The blot was blocked with blocking buffer
(10 mM Tris-Cl pH 7.5, 150 mM NaCl, 3% BSA) for 1 h at room
temperature and incubated with purified anti-T-SP1/3 antibodies
in a dilution of 1:500 overnight at 48C. As a secondary antibody,
the goat anti-rabbit IgG antibody linked with horseradish per-
oxidase (Dako, Glostrup, Denmark) was used in a dilution of
1:20 000. Visualization was carried out as described above. For
the detection of T-SP1-EGFP fusion proteins, an anti-GFP anti-
body (Roche) was used in a dilution of 1:1000. A secondary
HRP-linked anti-mouse antibody (Santa Cruz Biotechnology
Inc.) was applied in a dilution of 1:3000.
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